Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
Abstract The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-eff...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-91540-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850208342265298944 |
|---|---|
| author | Chunyan Yan Zhengxiong Li Jiayan Li Quan Zhao Wenxiu Cao Shuqing Li Ruigang Diao |
| author_facet | Chunyan Yan Zhengxiong Li Jiayan Li Quan Zhao Wenxiu Cao Shuqing Li Ruigang Diao |
| author_sort | Chunyan Yan |
| collection | DOAJ |
| description | Abstract The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-effectiveness of benmelstobart (B) and anlotinib (A) plus etoposide and carboplatin (EC) as first-line treatment options for patients with ES-SCLC in China. From the perspective of Chinese healthcare system, a three-state partitioned survival model was employed. The cycle length was set at three weeks, and the time horizon of the study was set as lifetime horizon. Total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) as primary outputs of the model. Among them, the cost, and utility values were respectively derived from the YAOZHI database, and published literature on the subject. At the same time, in order to assess the impact of parameter uncertainty on the model outputs, scenario and sensitivity analyses were carried out. The results showed that compared with the EC group, the ICER for the B + A + EC group was $141,623.44/QALY, and the ICER for the A + EC group was $45,353.46/QALY, which were both higher than the willingness-to-pay (WTP) threshold ($38,024.68/QALY). Sensitivity analysis verified the robustness of the model. Scenario analysis showed that charitable donations and cut-price could raise the likelihood of being cost-effective for benmelstobart and anlotinib. B + A + EC and A + EC are considered unlikely to be cost-effective strategies for first-line treatment of ES-SCLC in China. However, reducing the costs of benmelstobart and anlotinib may enhance the cost-effectiveness of these treatment regimens. |
| format | Article |
| id | doaj-art-e4e433848b0e4dc6a3bee20d69eb5192 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e4e433848b0e4dc6a3bee20d69eb51922025-08-20T02:10:16ZengNature PortfolioScientific Reports2045-23222025-03-0115111110.1038/s41598-025-91540-9Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in ChinaChunyan Yan0Zhengxiong Li1Jiayan Li2Quan Zhao3Wenxiu Cao4Shuqing Li5Ruigang Diao6Department of Pharmacy, Yantai Yuhuangding HospitalSchool of Medical Informatics and Engineering, Xuzhou Medical UniversityDepartment of Pharmacy, Yantai Yuhuangding HospitalDepartment of Pharmacy, Yantai Yuhuangding HospitalDepartment of Pharmacy, Yantai Yuhuangding HospitalDepartment of Pharmacy, Yantai Yuhuangding HospitalDepartment of Pharmacy, Yantai Yuhuangding HospitalAbstract The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-effectiveness of benmelstobart (B) and anlotinib (A) plus etoposide and carboplatin (EC) as first-line treatment options for patients with ES-SCLC in China. From the perspective of Chinese healthcare system, a three-state partitioned survival model was employed. The cycle length was set at three weeks, and the time horizon of the study was set as lifetime horizon. Total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) as primary outputs of the model. Among them, the cost, and utility values were respectively derived from the YAOZHI database, and published literature on the subject. At the same time, in order to assess the impact of parameter uncertainty on the model outputs, scenario and sensitivity analyses were carried out. The results showed that compared with the EC group, the ICER for the B + A + EC group was $141,623.44/QALY, and the ICER for the A + EC group was $45,353.46/QALY, which were both higher than the willingness-to-pay (WTP) threshold ($38,024.68/QALY). Sensitivity analysis verified the robustness of the model. Scenario analysis showed that charitable donations and cut-price could raise the likelihood of being cost-effective for benmelstobart and anlotinib. B + A + EC and A + EC are considered unlikely to be cost-effective strategies for first-line treatment of ES-SCLC in China. However, reducing the costs of benmelstobart and anlotinib may enhance the cost-effectiveness of these treatment regimens.https://doi.org/10.1038/s41598-025-91540-9Cost-effectivenessBenmelstobartAnlotinibExtensive-stage small cell lung cancerPartitioned survival modelFirst-line |
| spellingShingle | Chunyan Yan Zhengxiong Li Jiayan Li Quan Zhao Wenxiu Cao Shuqing Li Ruigang Diao Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China Scientific Reports Cost-effectiveness Benmelstobart Anlotinib Extensive-stage small cell lung cancer Partitioned survival model First-line |
| title | Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China |
| title_full | Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China |
| title_fullStr | Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China |
| title_full_unstemmed | Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China |
| title_short | Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China |
| title_sort | cost effectiveness of benmelstobart and anlotinib plus chemotherapy as first line therapy for extensive stage small cell lung cancer in china |
| topic | Cost-effectiveness Benmelstobart Anlotinib Extensive-stage small cell lung cancer Partitioned survival model First-line |
| url | https://doi.org/10.1038/s41598-025-91540-9 |
| work_keys_str_mv | AT chunyanyan costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina AT zhengxiongli costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina AT jiayanli costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina AT quanzhao costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina AT wenxiucao costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina AT shuqingli costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina AT ruigangdiao costeffectivenessofbenmelstobartandanlotinibpluschemotherapyasfirstlinetherapyforextensivestagesmallcelllungcancerinchina |